Contemporary Medical Management of Primary Hyperparathyroidism:A Systematic Review by Leere, Julius Simoni et al.
 
  
 
Aalborg Universitet
Contemporary Medical Management of Primary Hyperparathyroidism
A Systematic Review
Leere, Julius Simoni; Karmisholt, Jesper; Robaczyk, Maciej ; Vestergaard, Peter
Published in:
Frontiers in Endocrinology
DOI (link to publication from Publisher):
10.3389/fendo.2017.00079
Creative Commons License
CC BY 4.0
Publication date:
2017
Document Version
Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Leere, J. S., Karmisholt, J., Robaczyk, M., & Vestergaard, P. (2017). Contemporary Medical Management of
Primary Hyperparathyroidism: A Systematic Review. Frontiers in Endocrinology, 8, [79].
https://doi.org/10.3389/fendo.2017.00079
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to
the work immediately and investigate your claim.
Downloaded from vbn.aau.dk on: November 30, 2020
April 2017 | Volume 8 | Article 791
Review
published: 20 April 2017
doi: 10.3389/fendo.2017.00079
Frontiers in Endocrinology | www.frontiersin.org
Edited by: 
Patrizia D’Amelio, 
University of Turin, Italy
Reviewed by: 
Jan Josef Stepan, 
Charles University in 
Prague, Czechia  
Jameela Banu, 
University of Texas Rio Grande 
Valley Rio Grande City, USA
*Correspondence:
Julius Simoni Leere 
j.leere@rn.dk
Specialty section: 
This article was submitted 
to Bone Research, 
a section of the journal 
Frontiers in Endocrinology
Received: 31 December 2016
Accepted: 30 March 2017
Published: 20 April 2017
Citation: 
Leere JS, Karmisholt J, Robaczyk M 
and Vestergaard P (2017) 
Contemporary Medical Management 
of Primary Hyperparathyroidism: 
A Systematic Review. 
Front. Endocrinol. 8:79. 
doi: 10.3389/fendo.2017.00079
Contemporary Medical Management 
of Primary Hyperparathyroidism:  
A Systematic Review
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1 Department of Clinical Medicine, Aalborg University, Aalborg, Denmark, 2 Department of Endocrinology, Aalborg University, 
Aalborg, Denmark
introduction: Primary hyperparathyroidism is increasingly an asymptomatic disease 
at diagnosis, but the recognized guidelines for management are based on evidence 
obtained from studies on patients with symptomatic disease, and surgery is not always 
indicated. Other patients are unable to undergo surgery, and thus a medical treatment 
is warranted. This systematic review provides an overview of the existing literature on 
contemporary pharmaceutical options available for the medical management of primary 
hyperparathyroidism.
Methods: Databases of medical literature were searched for articles including terms 
for primary hyperparathyroidism and each of the included drugs. Data on s-calcium, 
s-parathyroid hormone, bone turnover markers, bone mineral density (BMD) and hard 
endpoints were extracted and tabulated, and level of evidence was determined. Changes 
in s-calcium were estimated and a meta-regression analysis was performed.
Results: The 1,999 articles were screened for eligibility and 54 were included in the 
review. Weighted mean changes calculated for each drug in s-total calcium (mean 
change from baseline ± SEM) were pamidronate (0.31 ± 0.034 mmol/l); alendronate 
(0.07  ±  0.05  mmol/l); clodronate (0.20  ±  0.040  mmol/l); mixed bisphosphonates 
(0.16 ± 0.049 mmol/l); and cinacalcet (0.37 ± 0.013 mmol/l). The meta-analysis revealed 
a significant decrease of effect on s-calcium with time for the bisphosphonates (Coef. 
−0.049 ± 0.023, p = 0.035), while cinacalcet proved to maintain its effect on s-calcium 
over time. Bisphosphonates improved BMD while cinacalcet had no effect.
Discussion: The included studies demonstrate advantages and drawbacks of the 
available pharmaceutical options that can prove helpful in the clinical setting. The great 
variation in how primary hyperparathyroidism is manifested requires that management 
should rely on an individual evaluation when counseling patients. Combining resorptive 
agents with calcimimetics could prove rewarding, but more studies are warranted.
Keywords: primary hyperparathyroidism, parathyroid adenoma, medical treatment, drug therapy, bisphosphonates, 
cinacalcet
iNTRODUCTiON
Management of primary hyperparathyroidism is a topic of much debate. Surgery is today the 
only curative treatment option. Changes in the symptomatology and stage of disease at diagno-
sis have led to an increasing number of patients who do not fulfill criteria for surgery, but are 
managed with active surveillance (1). Some studies suggest that these patients over time might 
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experience disease progression or develop complications such as 
osteoporosis, cardiovascular disease, or renal calculi (2–5). Other 
patients are unable to undergo surgery due to comorbidity or 
fear of complications. For these reasons, a medical alternative is 
highly warranted. In the past, several different pharmaceutical 
options have been investigated. Studies have reported trials utiliz-
ing estrogens and estrogen-related compounds (6), calcitonin (7), 
oral phosphate (8), strontium ranelate (9), somatostatin analogs 
(10, 11), vitamin-D and calcium supplementations (12). Some 
of these studies have shown minor effects on s-calcium-levels, 
bone mineral density (BMD), and other endpoints. Due to lack of 
effect, contraindications, and unwanted or unacceptable risks of 
drug-related adverse events, these drugs are today not considered 
realistic alternatives to surgery (13). The purpose of this review 
therefore was to describe the available literature on classes of 
drugs that today are considered options in the medical therapy of 
primary hyperparathyroidism where surgery for various reasons 
cannot be performed. This systematic review has its main focus 
on classes of antiresorptive medication (mainly bisphosphonates) 
and calcimimetics (cinacalcet).
MATeRiALS AND MeTHODS
Literature Search and Selection Strategy
Included articles were found searching Medline (1946–2016), 
Embase (1947–2016), and The Cochrane Library (inception–2016). 
Literature searches were conducted by an experienced librar-
ian with input from the principal investigator. Searched terms 
included primary hyperparathyroidism, parathyroid adenoma, 
and each of the included pharmaceutical agents. Included drugs 
were all groups of bisphosphonates, isoflavones, denosumab, 
blosozumab, romosozumab, odanacatib, cinacalcet, etelcalcetide, 
telcalcetide, and velcalcetide with all available product names 
and synonyms. The final search was performed September 26th 
2016, which thus is the inclusion limit. All published full-text 
articles in English including medical treatment of primary 
hyperparathyroidism as a main subject were considered eligible. 
In vitro/animal studies, abstracts, review articles, and case reports 
with less than five subjects were not eligible due to lack of data 
and comparability. A thorough search strategy can be found in 
the Supplementary Material, in the included search string. An 
electronic review protocol can be found at www.crd.york.ac.uk/
prospero/, registration number: CRD42016053702. We followed 
the PRISMA guidelines (www.prisma-statement.org).
Study Selection
Articles were initially screened independently by title and abstract 
by two authors (Julius Simoni Leere and Peter Vestergaard). Lists 
with the articles each of the authors had found eligible were 
compared and discussed. In case of disagreement between the 
authors, the full-text article was acquired for evaluation. The 
obtained full-text articles were excluded if they did not include 
medical treatment of primary hyperparathyroidism as a main 
subject, or did not include one or more of the drugs of inter-
est (i.e., drugs used in the search strategy). Studies that lacked 
data or consistency in reporting on efficacy of the drugs, or did 
not fulfill the given criteria for eligibility mentioned previously 
in the search strategy were excluded. Change in s-total calcium 
(albumin adjusted) was a primary endpoint and necessary in 
statistical analysis. Studies that failed to report figures of either 
baseline or treatment levels of s-total calcium were excluded from 
the meta-calculations, but included in the tables for evaluation in 
the systematic review.
Data extraction and Handling
If feasible, the following data were extracted and tabulated 
from each included study: test-drug, dosage used, patient and 
study characteristics, treatment duration, s-calcium at baseline, 
s-calcium when treated, change in parathyroid hormone (PTH), 
change in urinary calcium excretion or calcium/creatinine ratio, 
change in bone turnover markers, change in BMD as measured 
by dual energy X-ray absorptiometry (DXA) in terms of a T/Z-
score or percental change at different sites, and evaluation of 
hard endpoints (e.g., fractures, adverse events, stone formation, 
etc.). Differences and changes were described as mean  ±  SD/
SEM where possible, alternatively as change in percent or simply 
as decrease/increase depending on the available data. Due to 
possible variation in arrays and machinery used for analysis of 
bone turnover markers and BMD, outcomes for BMD and bone 
turnover markers were classified as either increase/decrease or no 
change for each individual study. This minimized the influence 
from differences in arrays and DXA-scanners used by the differ-
ent studies. Values reported were usually measured at either the 
last measurement performed before termination for long-term 
treatment studies, at nadir/peak-values for short-term/single 
infusion studies, or as otherwise stated (see Tables S1–S6 in the 
Supplementary Material).
s-Calcium Levels
s-total calcium was handled differently from the other variables: 
if no actual values including SD/SEM were stated in the articles, 
values were obtained from graphs and figures if possible. If only 
ranges were provided, the mean was deducted by taking the aver-
age of the stated extremes.
Level of evidence
All included studies were graded according to the Oxford Centre 
for Evidence-Based Medicine 2011 Levels of Evidence (OCEBM 
levels) (14). The category applied was evaluation of treatment 
benefits. Level for each study was assessed initially depending on 
the type of study and could be graded up or down depending 
on study quality, precision in reporting, population size, and 
effect size. Randomized controlled trials (RCTs) were considered 
most reliable (grade 2), followed by non-randomized controlled 
cohorts/follow-up studies (grade 3), and finally observational 
uncontrolled studies, case series, and reports (grade 4). Levels 
were evaluated, discussed, and approved by two authors (Julius 
Simoni Leere and Peter Vestergaard). Study quality was evaluated 
for each report by exploring factors that could possibly introduce 
bias, e.g., randomization, blinding, withdrawals and dropouts, 
as well as applied methods of analysis and reporting. For each 
drug-group, a mean level of provided evidence was calculated 
(see Table 1).
Study Drug OCeBM level
Saponaro et al. (66) Cinacalcet 4
Schwarz et al. (67) Cinacalcet 4
Mean level of evidence—cinacalcet: 3.47
ipriflavone
Mazzuoli et al. (68) Ipriflavone 4
TABLe 1 | Oxford Center for evidence-Based Medicine Levels of 
evidence.
Study Drug OCeBM level
Pamidronate
van Breukelen et al. (15) Pamidronate 3
Jansson et al. (16) Pamidronate 4
Ishimura et al. (17) Pamidronate 4
Schmidli et al. (18) Pamidronate 2
Ammann et al. (19) Pamidronate 4
Jansson and Morgan (20) Pamidronate 4
Phitayakorn and McHenry (21) Pamidronate 4
Mean level of evidence—pamidronate: 3.57
Alendronate
LoCascio et al. (22) Alendronate 4
Khan et al. (23) Alendronate 2
Adami et al. (24) Alendronate 4
Szymczak and Bohdanowicz-Pawlak (25) Alendronate 3
Akbaba et al. (26) Alendronate 2
Cesareo et al. (27) Alendronate 3
Chow et al. (28) Alendronate 2
Hassani et al. (29) Alendronate 3
Khan et al. (30) Alendronate 2
Makras et al. (31) Alendronate 4
Parker et al. (32) Alendronate 3
Rossini et al. (33) Alendronate 3
Mean level of evidence—alendronate: 2.92
Clodronate
Adami et al. (34) Clodronate 3
Shane et al. (35) Clodronate 2
Douglas et al. (36) Clodronate 4
Douglas et al. (37) Clodronate 4
Fang et al. (38) Clodronate 4
Hamdy et al. (39) Clodronate 4
Mean level of evidence—clodronate: 3.5
etidronate and other bisphosphponates
Horiuchi et al. (40) Etidronate 2
Kaplan et al. (41) Etidronate 4
Reasner et al. (42) Risedronate 4
Tournis et al. (43) Risedronate 3
Rossini et al. (44) Neridronate 4
Segula et al. (45) Mixed 4
Lee et al. (46) Mixed 4
Vera et al. (47) Mixed 4
Yeh et al. (48) Mixed 4
Mean level of evidence—etidronate and other bisphosphonates: 3.67
Cinacalcet
Brardi et al. (49) Cinacalcet 3
Cetani et al. (50) Cinacalcet 4
Giusti et al. (51) Cinacalcet 4
Filopanti et al. (52) Cinacalcet 2
Marotta et al. (53) Cinacalcet 4
Faggiano et al. (54) Cinacalcet 4
Keutgen et al. (55) Cinacalcet 4
Khan et al. (56) Cinacalcet 2
Luque-Fernández et al. (57) Cinacalcet 4
Moyes et al. (58) Cinacalcet 4
Marcocci et al. (59) Cinacalcet 4
Norman et al. (60) Cinacalcet 4
Peacock et al. (61) Cinacalcet 2
Peacock et al. (62) Cinacalcet 4
Peacock et al. (63) Cinacalcet 3
Sajid-Crockett et al. (64) Cinacalcet 4
Shoback et al. (65) Cinacalcet 2
(Continued)
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Statistical Analysis
Data on s-total calcium from individual trials were pooled as 
applicable to calculate weighted mean change and SEM for each 
included drug. Weighting was applied to data taking into account 
population size and SD of each included project. Non-standard 
units on s-calcium reported in the articles were converted to stand-
ard international units (millimoles per liter). Normality of data 
was checked using QQ-plots in comparison with a standardized 
QQ-plot catalog. Meta-regression was performed using STATA 8.0 
(Stata Corporation, College Station, TX, USA) to evaluate impact 
of baseline s-calcium levels, treatment duration, and applied drug 
on effect of treatments in terms of change in means s-calcium level 
over time. Time was transformed into a natural-logarithmic scale 
in the process of investigating time effect on bisphosphonate treat-
ment. Where only grouped outcomes such as increase in BMD 
were possible to analyze, a binomial distribution was assumed, and 
the outcome tested against the assumed probability distribution.
ReSULTS
Study Selection
The literature search generated 1,999 articles: Embase (1,427), 
Medline (490), and Cochrane Library (82) (see flowchart, 
Figure 1). After removal of duplicates 1,582 articles remained. 
Of these 1,426 were deemed ineligible in the screening process 
of titles and abstracts due to following reasons: language other 
than English (118), in  vitro/animal studies (5), review articles 
(117), and irrelevance for this review (1,186). In total, 156 
articles were ordered from the Library of Aalborg University 
Hospital, to be assessed in full text. A total of 44 were published 
(conference) abstracts with no obtainable corresponding full-text 
article. A total of 41 were case reports with less than 5 included 
cases. One was a commentary on another article. One could not 
be delivered by the library (69). A total of 69 full-text articles 
were studied for eligibility. Fifteen were found ineligible; nine of 
these were focused on pharmaceutical agents outside the scope 
of this review [five vitamin-D supplementation and calcium 
(12, 70–73), two octreotide (10, 11), one hormone replacement 
therapy (6), one Strontium Ranelate (9)]; two were review articles 
(74, 75); two had no data on effect of the included drugs (76, 77); 
one had a main focus other than medical treatment of primary 
hyperparathyroidism (78); and one was found incomparable to 
the remaining studies due to incoherent reporting and few sub-
jects (79). Fifty-four articles were thus included in this review. 
The articles were distributed between drug-classes as follows: 7 
pamidronate, 12 alendronate, 6 clodronate, 2 etidronate, 2 rise-
dronate, 1 neridronate, 4 mixed bisphosphonates, 19 cinacalcet, 
TABLe 1 | Continued
FiGURe 1 | PRiSMA flowchart (80).
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and 1 examining ipriflavone. See Tables S1–S6 in Supplementary 
Material for results of the individual reports. Forty studies pro-
vided sufficient data (figures on s-calcium including SD) to be 
included in the meta-regression on treatment effect on s-calcium 
levels over time, and the calculations of weighted means in 
change of s-calcium. The distribution of studies included in the 
meta-regression was as follows: 7 pamidronate, 9 alendronate, 
3 clodronate, 1 etidronate, 1 risedronate, 3 mixed bisphospho-
nates, and 16 cinacalcet. Six of these studies provided data by 
means of graphs and figures (16, 18, 28, 30, 32, 56) and two 
(17, 58) reported only in terms of range, and values therefore 
were acquired as previously described.
Pamidronate
The seven studies concerning management with pamidronate 
(15–21) were all studies of short-term treatment (see Table S1 in 
Supplementary Material). Duration of treatment ranged from a 
single infusion to a few weeks, and follow-up was correspondingly 
short. Mean level of evidence was 3.57. All studies report a significant 
reduction of s-calcium within days of treatment. Weighted change 
of mean in s-total calcium was (0.31  ±  0.034  mmol/l). Five 
studies report a transient rise in s-PTH, which decreased again 
as s-calcium returned toward baseline. Similarly, bone turnover 
decreased as measured by urinary calcium excretion and lower-
ing of biochemical markers of bone resorption and formation 
(p-alkaline phosphatase; urinary hydroxyproline; p-osteocalcin). 
Due to the limited time-frame of performed studies, no measures 
of change in BMD were available. No serious drug-related adverse 
events were reported.
Alendronate
Twelve studies reported on the use of alendronate (22–33) 
(see Table S2 in Supplementary Material). Range of treatment 
duration was 5 days to 2 years, with nine reports of ≥48 weeks. 
OCEBM Level of Evidence was on average 2.92. s-Total calcium 
decreased on average marginally (0.07 ± 0.05 mmol/l)—this figure 
is based on data from nine studies [two short-term (22, 24) and 
seven long-term studies (26–32)]. However, it is worth noticing 
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that several of the studies reporting on long-term treatment 
found an initial significant decrease in s-calcium-levels, which 
lasted around 6 months, but then over time rose toward baseline 
(25, 26, 28, 32, 33). A corresponding pattern could be seen in PTH 
levels, which rose in the majority of studies. Of the three short-
term studies (≤2 months) in the alendronate group, two found 
a decrease similar to that achieved in the pamidronate group 
(22, 24) whereas one found no change (31). Bone turnover 
decreased in all studies reporting on the issue in terms of 
biochemical turnover markers. Urinary calcium excretion was 
reported to either decrease or remain unchanged in eight studies 
whereas two studies found an insignificant increase. All nine 
long-term studies report on increases in BMD at all sites measure 
(except one study that finds an insignificant decrease in BMD 
in distal radius, but increase at all other sites). BMD-gains are 
reported to be more pronounced in bone rich in trabecular tissue 
(lumbar spine and hip/femoral neck) compared to compartments 
richer in cortical tissue (distal radius). The finding of an increase 
in BMD in all nine studies was significant as a decline is usually 
expected with age (p < 0.01 by binomial distribution assuming a 
likelihood of 5% for an increase in BMD).
Clodronate
Clodronate was evaluated in a total of six studies (34–39) of 
which only three (35, 37, 39) had data valid for the calculation of 
an average decrease in s-total calcium of (0.20 ± 0.040 mmol/l) 
(see Table S3 in Supplementary Material). Duration of treatment 
was 2  weeks to 3  years. Short-term treatment was associated 
with a decrease in s-calcium in all five studies. Among these, the 
decrease was statistically significant in three. The only long-term 
study in the clodronate group (38) did not report figures on s-total 
calcium changes. Three studies report PTH increases, one finds no 
change and one report a slight decrease. All five studies describing 
changes in u-calcium changes find a treatment-related decrease. 
The same five studies report decreases in urinary hydroxyproline 
levels indicating a lowered bone resorption. Alkaline phosphatase 
is reported with some controversy between studies: three finds 
a slight decrease, two finds an increase (insignificant), and one 
finds no change. None of the studies report on changes in BMD. 
One study finds an increased rate of renal loss of function as well 
as a lower New York Heart Association Functional Classification 
(NYHA) and American Society of Anesthesiologists physical 
status classification (ASA) scores in a high morbidity patient-
group compared to a group treated surgically; however, it remains 
unclear whether this can be related to the treatment with clo-
dronate (38). Evidence level was on average 3.5.
Mixed bisphosphonates
The articles concerning etidronate (2) (40, 41), risedronate (2) 
(42, 43), neridronate (1) (44), and mixed bisphosphonates (4) 
(45–48) were, due to the limited number of studies, pooled 
into one group called mixed bisphosphonates (see Table S4 in 
Supplementary Material). The articles reporting on effects of 
etidronate, risedronate, and neridronate used one drug only for all 
included subjects, whereas the articles on mixed bisphosphonates 
used a variety of different bisphosphonates within the individual 
study. One article on etidronate (40), one on risedronate (42), 
and three reporting on mixed bisphosphonates (45–47) provided 
data to the calculation of an average decrease in s-calcium of 
(0.16 ± 0.049 mmol/l). Treatment duration varied from a single 
dose treatment to 5 years. The OCEBM Level of Evidence in this 
pooled group was 3.67.
The five studies in this heterogeneous group reporting on a 
single bisphosphonates describe variable decreases in s-calcium 
and a simultaneous rise in PTH levels. Several articles thus 
described a pattern similar to what was observed in the articles 
of the alendronate group with an initial effect and later reversal 
(41, 44). Bone turnover markers [alkaline phosphatase, collagen 
type 1 cross-linked C-telopeptide (CTX), and osteocalcin] and 
urinary calcium excretion all decreased. The studies reporting on 
BMD-changes, demonstrated increases over time, and as in the 
other bisphosphonate groups this was markedly better at trabecu-
lar sites. One study concerning risedronate reported in addition 
to aBMD on a peripheral quantitative computed tomography 
analysis to evaluate the volumetric BMD, and found only very 
limited change from baseline (+0.24% at a trabecular site and 
−0.26% at a cortical site) (43).
Four articles describe cohorts treated with a range of bispho-
sphonates. Three long-term treatment regimens (45, 47, 48), 
and one short term (46). The short-term study describes the 
use of bisphosphonates in pretreatment of patients undergoing 
parathyroidectomy and claims that bisphosphonate treatment 
can prevent development of hungry bones syndrome [although 
the number of patients treated is very limited (n = 6)]. The three 
long-term studies have large populations included, but the drop-
out rate, especially in Ref (48). is high, leaving a risk of adherence 
bias. Only two out of the three (45, 47) reports on s-calcium 
which is unchanged in one and decreases in the other during 
treatment, PTH, CTX, and alkaline phosphatase are reported to 
decline. Vera et al. (47) reports a small and insignificant decline in 
BMD, whereas Yeh et al. and Segula et al. (45, 48) in accordance 
with most other studies report an increase at spine and hip. The 
prior study also reports a markedly increased risk of fractures 
compared to patients treated surgically (PTX) as well as controls, 
but the bisphosphonate subgroup also did have a much lower 
BMD at baseline compared to the other two groups. Segula et al. 
(45) reports no change in fragility fracture-rate when treated 
compared to when not treated with bisphosphonates.
Cinacalcet
Cinacalcet was tested in 19 studies (49–67), 16 of which data 
on s-total calcium were pooled to estimate a weighted mean 
decrease of (0.37 ± 0.013 mmol/l) (see Table S5 in Supplementary 
Material). The mean level of evidence for the whole group was 
3.47. Duration of the studies ranged from 15 days to 44 months. 
s-calcium decreased significantly and remained so in all 19 
articles throughout the whole spectrum of treatment periods. 
This decrease was reported in ionized calcium as well (50–52, 64) 
and was also proved to be present in hereditary forms of primary 
hyperparathyroidism (51, 52, 58, 66).
Cinacalcet’s ability to lower PTH was intensely studied. In 18 
studies, PTH is reported to decrease (significantly in 15) while 
one saw no change. The effect is reported to be smaller than that 
FiGURe 2 | effect of bisphosphonates on s-calcium over time.
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on s-calcium, and normalization of mean levels rarely occur. A 
few studies described how levels varied in relation to time since 
ingestion, and nadir was reported to be 2–4 h post dose, where-
after it rose markedly and peaked pre-dose (65). There seems to 
be a tendency toward a lowering of urinary calcium excretion, 
with insignificant decreases reported in six studies, one showed 
significant decrease, two reported no change, and one an insig-
nificant increase. The effect on bone turnover as measured by 
biomarkers appears to be diverse with two articles reporting a 
decline, four finding no change, and four indicating an increase. 
This is in accordance with no change on average (p  =  0.79 by 
binomial distribution assuming a 33% likelihood of decline). 
Only a few of the studies performed measurements of BMD. Two 
of those studies report a marginal increase, two a decrease and 
five no change. This points at no overall change in BMD (p = 0.39 
by binomial distribution assuming a 33% likelihood of decline). 
One study combined cinacalcet with alendronate and found the 
increase in BMD similar to that of the bisphosphonate therapy 
alone, but also maintained a significant decrease in s-calcium, 
u-calcium excretion, s-PTH, and bone turnover markers (alkaline 
phosphatase) throughout the year the study lasted (54). Like in 
the bisphosphonate groups the reporting of hard endpoints was 
very sparse. One study demonstrated a decrease in formation of 
nephrolithiasis and diameter of stones when treated with cinacal-
cet compared to standard treatment (49). Nine studies reported 
of drug-related adverse events. Two articles reported on HRQoL 
(health-related quality of life); one found an increase in 50% of 
patients with intractable primary hyperparathyroidism with the 
introduction of cinacalcet (59), the other found no difference 
compared to placebo (56). The most common side effects by 
far were nausea and gastrointestinal discomfort, myalgia and 
hypocalcemia (non-fatal).
Meta-Regression on Treatment effects on 
s-Total Calcium over Time
One of the purposes with this review was to evaluate the impact 
of time on treatment efficacy in terms of effect on s-calcium. This 
was done using a meta-regression-analysis. In addition to treat-
ment duration we investigated whether baseline s-total calcium 
levels and drug class had an impact on the observed change. 
When performing the analysis on data on bisphosphonates with 
time being logarithmic transformed, it becomes evident that an 
increase in pretreatment s-calcium levels is positively correlated 
with the degree of decrease in s-calcium during treatment (Coef. 
0.49  ±  0.16, p  =  0.002). Treatment duration is negatively cor-
related to change of s-calcium (Coef. −0.049 ± 0.023, p = 0.035), 
and class of bisphosphonate utilized has no impact on effect 
(p  =  0.227). If time is not transformed, treatment duration 
becomes insignificant (Coef. −0.00014 ± 0.00008, p = 0.075), and 
drug class becomes significant (p < 0.000), possibly due to the 
variation in treatment duration described between the different 
classes of bisphosphonate.
Figure  2 shows how rapidly serum calcium decreases upon 
initiation of bisphosphonate. However, the decrease diminishes 
over time. This pattern is confirmed in Figure  3 where time 
has been transformed on a logarithmic scale, and a trend line 
clearly indicates a decrease in effect over time. The distribution of 
FiGURe 3 | effect of bisphosphonates over time logarithmically transformed.
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short- and long-term regimens between classes of bisphosphonates 
(e.g., all pamidronate studies had a short duration vs. most alen-
dronate studies being long term), do thus not appear to make a 
clear difference in effect. Hence, the much smaller decrease in 
mean s-total calcium as reported previously for alendronate vs. 
pamidronate (0.066 ± 0.05 vs. 0.31 ± 0.034) may be attributed to 
a difference in time-span in the reported studies.
Figure 4 illustrates the effect of cinacalcet on s-total calcium 
over time. In accordance with results reported in the individual 
included studies, we find that the effect does not appear to change 
over time, but s-calcium remains lowered compared to baseline 
values throughout the treatment period.
DiSCUSSiON
In this systematic review and meta-analysis, we find a significant 
decrease of effect on plasma calcium with time for the bisphos-
phonates, while cinacalcet seems to maintain its effect on plasma 
calcium over time. Cinacalcet did not seem to have major effects 
on BMD and bone turnover, while long-term treatment with 
bisphosphonates seemed to increase BMD.
This illustrates the strengths and drawbacks of the pharma-
ceutical agents that are available at present. Bisphosphonates 
lower the levels, s-calcium levels, transiently and can be utilized 
in acute treatment, but are inefficient in regulating calcium-levels 
in the long term. As described by the meta-regression, baseline 
calcium-levels are positively correlated with the effect of bispho-
sphonate treatment on s-calcium, whereas the specific class of 
bisphosphonates appears to be less important when “adjusting” for 
distribution of treatment duration between drugs by transform-
ing time to a logarithmic scale. The rebound of calcium-levels is 
probably due to the reported concomitant surge in s-PTH, which 
among other possible mechanisms will affect renal reabsorption 
of calcium, elevating s-calcium. On the other hand bisphospho-
nates lower bone turnover as shown by biochemical markers and 
significantly increase BMD especially at trabecular sites. Data on 
hard endpoints such as fracture-incidence are very sparse.
Cinacalcet proved to be efficient in lowering and normalizing 
s-calcium throughout the whole specter of studied disease sever-
ity, and, contrary to bisphosphonates, did not lose its calcium-
lowering capability over time. It simultaneously lowers s-PTH, 
albeit to a less significant degree. It lowers u-calcium excretion 
minutely, possibly having an attenuating effect on renal stone 
disease. Bone turnover appears unchanged, and BMD does not 
improve. Hard endpoints other than brief reports on adverse 
events have rarely been evaluated. Due to the short period of time, 
cinacalcet has been available, there are only very limited data on 
long-term effects. This includes possible drug-related adverse 
events, and the future studies will need to focus on cinacalcet’s 
impact on bone turnover and hard endpoints.
A recent meta-analysis (81) finds only very limited evidence 
on clinical benefits of surgery vs. active surveillance in patients 
with mild primary hyperparathyroidism. The authors reviewed 
variables such as changes in BMD, quality of life measures, 
and hard endpoints such as kidney stones, fractures, and car-
diovascular events. No convincing evidence of improvement 
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by PTX was found for any of these endpoints, except a single 
RCT showing a minute effect on BMD. Although follow-up was 
short (max. 5  years), and the number of studies and patients 
relatively low, this demonstrates an important problem in the 
management of primary hyperparathyroidism of today: many 
patients are diagnosed in an asymptomatic stage of the disease, 
and all the evidence we apply in our counseling to them is based 
on studies involving cohorts at much higher risk. Our study 
involved patients of all disease severities and is therefore not 
directly comparable to the group investigated by Singh Ospina 
et al. (81). Furthermore, we studied the effects of drug interven-
tion whereas Singh Ospina et  al. (81) compared conservative 
management to surgical treatment. The clinical implications 
of our study for the group of asymptomatic patients, however, 
do appear relevant. If active surveillance proves to be equal to 
surgery on a long-term basis for this large group of patients, the 
addition of, e.g., bisphosphonates could turn out beneficial in 
treating and preventing the development of osteoporosis in this 
group of patients as an alternative to surgery. More studies on 
this issue and a possible medical alternative to surgery therefore 
seem warranted.
Only one article (54) had a main focus on a combined treat-
ment (alendronate and cinacalcet), though the thought of utiliz-
ing the bone-strengthening effects of an antiresorptive agent in 
combination with the hormone- and calcium-regulating features 
of cinacalcet appears promising. Also noteworthy was the fact that 
no trials had been conducted testing the effects of denosumab 
or zoledronic acid in primary hyperparathyroidism. New drugs 
under evaluation such as etelcalcitide could also turn out to be 
valuable additives to the current options in the future treatment of 
primary hyperparathyroidism.
This study has its limitations due to relatively few reports on 
each drug class, the variability in duration of treatment reported 
from one drug to the other, and in low general level of evidence 
(small study-populations, few RCTs, inconsistency in reporting 
results, risk of bias, and confounders of the included studies). 
Usually serum calcium is tightly regulated and the variation is 
small. Influence from various assays used by the studies cannot 
be excluded, but must be regarded as minor. The calculated mean 
s-calcium levels and SDs were in one case based on a ranges (17) 
and in seven cases based on figures obtained from graphs (16, 18, 
28, 30, 32, 53, 56), giving a risk of minor deviations from the exact 
values due to reading/printing imprecisions. Such deviations 
would however only have low impact on the meta-regression-
analysis and calculated means.
In conclusion, bisphosphonates seem to have a short-lived 
(<6 months) effect on plasma calcium, but a positive effect on 
BMD. By contrast, cinacalcet maintains a long-term effect on 
plasma calcium, but does not improve BMD.
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